Tech Company Financing Transactions

Ancora Biotech Funding Round

Lightspeed Venture Partners and SR One Capital Management participated in a $60 million Series A funding round for Ancora Biotech. The funding round was announced on 6/9/2022.

Transaction Overview

Company Name
Ancora Biotech
Announced On
6/9/2022
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series A
Investors

Lightspeed Venture Partners (Lead Investor)

SR One Capital Management (Lead Investor)

Proceeds Purpose
Proceeds purposes were not disclosed.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
953 Roble Ridge Road
Palo Alto, CA 94306
CA
Phone
Undisclosed
Website
www.ancorabiotech.com
Email Address
Undisclosed
Overview
Ancora Biotech LLC is a privately held company supporting the clinical development of three multi-specific antibodies. These three antibodies are held in separate spin-offs, namely: 1) TeneoTwo holds our clinical stage TNB-486 (anti-CD19xCD3) T cell engager for the safe and effective treatment of B cell cancers, 2) TeneoFour holds our preclinical TNB-738 (anti-CD38) enzyme inhibitor for the treatment of inflammatory and metabolic disorders in the elderly, and 3) TeneoTen holds our preclinical T cell engager (anti-HBVxCD3) for the curative treatment of chronic hepatitis B infections (CHB). TNB-738 is poised to enter Phase I clinical studies by early 2022 and we anticipate to select a clinical lead for CHB by mid-2022.
Profile
Ancora Biotech LinkedIn Company Profile
Social Media
Ancora Biotech Company Twitter Account
Company News
Ancora Biotech News
Facebook
Ancora Biotech on Facebook
YouTube
Ancora Biotech on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Roland Buelow
  Roland Buelow LinkedIn Profile  Roland Buelow Twitter Account  Roland Buelow News  Roland Buelow on Facebook
Chief Financial Officer
Stephen Dance
  Stephen Dance LinkedIn Profile  Stephen Dance Twitter Account  Stephen Dance News  Stephen Dance on Facebook
Chief Scientific Officer
Wim Schooten
  Wim Schooten LinkedIn Profile  Wim Schooten Twitter Account  Wim Schooten News  Wim Schooten on Facebook
Chief Technical Officer
Ute Schellenberger
  Ute Schellenberger LinkedIn Profile  Ute Schellenberger Twitter Account  Ute Schellenberger News  Ute Schellenberger on Facebook

 

 

Browse more venture capital transactions:

Prev: 6/9/2022: Seed-X Technologies venture capital transaction
Next: 6/9/2022: Shield AI venture capital transaction

 

Share this article

 

News on VC Transactions

Our team works diligently to report on funding rounds that are announced publicly. VC transactions reported here come from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.